Marijuana Doctor CardSchedule Now

Is Marijuana Schedule III Now? The 2026 Rescheduling, Explained

Published June 9, 2026 · Reviewed against the primary sources cited below

Yes — partially, and the nuance matters. On April 28, 2026, a DEA final rule (91 FR 22714) moved two specific categories to Schedule III: FDA-approved drug products containing marijuana, and marijuana covered by a state-issued medical marijuana license. Everything else — including recreational product and any cannabis outside state medical channels — remains Schedule I while a separate rulemaking continues.

What actually changed on April 28, 2026

The final rule took effect immediately on publication. It was issued under a treaty-obligation authority (21 U.S.C. 811(d)(1)), which let DEA act without completing the full notice-and-comment process that the broader rescheduling proposal is still going through. The rule's text is explicit: any form of marijuana other than an FDA-approved drug product or marijuana subject to a state medical marijuana license remains a Schedule I controlled substance.

The broader proposal to move all marijuana to Schedule III (proposed May 2024, 89 FR 44597) is still alive — DEA scheduled new hearings beginning June 29, 2026. Until that concludes, the United States runs a two-track system: medical cannabis dispensed under state licenses sits in Schedule III; everything else sits in Schedule I.

What it means for patients

For day-to-day patient life, less changed than headlines suggested. State program rules — cards, physician certifications, purchase limits — operate exactly as before; rescheduling didn't federalize or replace state programs. What changed is the federal legal posture of state-licensed medical cannabis: Schedule III substances are recognized as having accepted medical use, which strengthens research access and removes the punitive IRC 280E tax treatment from state-licensed dispensaries (which may eventually show up in prices).

What did NOT change yet: downstream federal agencies. ATF has not updated its firearms guidance, the IRS has not updated Publication 502 (so HSA/FSA funds still can't pay for cannabis), and DOT drug-testing rules for CDL drivers still treat THC as disqualifying. Interstate transport also remains illegal — the rule simultaneously amended import/export regulations so that even Schedule III marijuana requires DEA permits individual patients can't obtain.

Why getting a card matters more after rescheduling

The two-track system created a meaningful legal distinction between the same plant bought through a state medical program and bought anywhere else. With a state license behind it, your cannabis is a Schedule III substance; without one, it's Schedule I. That's the strongest legal argument for holding a valid medical card since state programs began.

The information on this site is for educational purposes only and is not medical or legal advice. Cannabis use carries risks; consult a licensed physician about whether medical cannabis is appropriate for you. Federal status (as of June 2026): marijuana dispensed under state medical licenses and FDA-approved cannabis products are Schedule III controlled substances; all other marijuana remains Schedule I under U.S. federal law. Laws cited here change; confirm current rules with the linked primary sources before acting on them.

FAQ

Quick answers

Is all marijuana federally legal now?

No. Schedule III is not legalization — it means recognized medical use with federal controls. And only FDA-approved products and state-licensed medical marijuana moved; recreational and unlicensed cannabis remain Schedule I.

Does rescheduling let me take my medicine across state lines?

No. Interstate transport remains a federal offense, and the 2026 rule explicitly requires DEA import/export permits for Schedule III marijuana that individual patients cannot obtain.

Will the rest of marijuana move to Schedule III too?

A separate rulemaking proposing exactly that is ongoing, with hearings that began in mid-2026. No final rule for general marijuana exists yet, and the outcome isn't guaranteed.

Sources & references

  1. Schedules of Controlled Substances: Rescheduling of FDA-Approved Products Containing Marijuana From Schedule I to Schedule III (Final Rule, 91 FR 22714) DEA / Federal Register, 2026.April 28, 2026 final rule: FDA-approved products and state-licensed medical marijuana moved to Schedule III; other marijuana remains Schedule I
  2. Rescheduling of Marijuana — Notice of Hearing (91 FR 22777) DEA / Federal Register, 2026.
  3. Drug Scheduling U.S. Drug Enforcement Administration, 2026.Federal scheduling framework
  4. IRS Publication 502 — Medical and Dental Expenses (Controlled Substances section) Internal Revenue Service, 2025.